Drugs / COVID-19 vaccine (Vero cells)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05033847 | Sep 2021 → Nov 2023 | Orthocoronavirinae infectious disease, pneumonia | National Vaccine and Serum Institute, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 vaccine (Vero cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05033847 ↗ |
| Modality | Vaccine | “COVID-19 vaccine (Vero cells)” NCT05033847 ↗ |
| Route | Intramuscular | “Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm” NCT05033847 ↗ |